RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)

This is a real-world observational study looking at how well asciminib — a newer targeted drug for a type of leukemia called chronic myeloid leukemia (CML) — works in patients in Saudi Arabia in everyday clinical practice. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase (CML-CP) - You have already been treated with at least 2 prior targeted therapies (TKIs) - You are currently taking asciminib as prescribed by your doctor, and started it no more than 6 months ago **You may NOT be eligible if...** - Asciminib is your first or second treatment for CML - You are already enrolled in another clinical trial - You refused to sign the consent form - Your doctor believes you would not be able to provide reliable medical history or attend follow-up visits Talk to your doctor to see if this trial is right for you.